evidoria

← Back to browse

Good practice Imported

Inven2 — Joint Technology-Transfer Office for University of Oslo & Oslo University Hospital

Norway · Oslo · See the Norway profile · See the Oslo profile

Evidence: Descriptive / self-reported Top 29% 76/100 · Ask Evidence Copilot about this practice

Nordic region's largest tech-transfer office, merging University of Oslo and Oslo University Hospital's TTOs: 2,072 inventions, 388 licences and 55 start-ups in its first decade.

2,072
Invention disclosures (2010-2020)
260
Patent applications filed (2010-2020)
388
Licence agreements concluded (2010-2020)
55
Start-up companies established (2010-2020)
NOK 500 million to NOK 15 billion
Market value of founded start-ups (2010-2020)
NOK 582 million
Licensing proceeds reinvested (2010-2020)
~1,500
Clinical-trial agreements initiated (by 2020)
~400
Ongoing clinical studies (2020)
32 people
Staff (mid-2020s)
Inven2 — Joint Technology-Transfer Office for University of Oslo & Oslo University Hospital

Details

Maturity
Established
Promoter
Inven2 AS (jointly owned by University of Oslo and Oslo University Hospital)
Period
2010–present
Region (NUTS)
NO01
Keywords
Life sciences, medtech, technology transfer, licensing

Context

Inven2 was established in 2010 through the merger of Medinnova (Rikshospitalet's technology-transfer office), Birkeland Innovasjon and the University of Oslo's own TTO, creating a single joint vehicle owned by the University of Oslo and Oslo University Hospital. It administers commercialisation for both owners plus all health trusts in the South-Eastern Norway Regional Health Authority.

Activities

Inven2 manages invention disclosures, patent filings, licensing and start-up formation across life sciences, medtech and technology transfer, with roughly two-thirds of its companies and licences in the life-sciences field. It operates with around 32 staff spanning legal, scientific and business-development expertise.

Results

Over 2010-2020 Inven2 recorded 2,072 invention disclosures, 260 patent applications, 388 licence agreements and 55 start-ups, with the market value of the start-ups it helped found growing roughly 30-fold (NOK 500 million to NOK 15 billion). It reinvested NOK 582 million of licensing proceeds and had initiated around 1,500 clinical-trial agreements, with about 400 clinical studies ongoing by 2020.

Conclusions

A licence with Merck for a cancer-pain drug candidate was described by Inven2's leadership as among the most valuable licence agreements ever granted in Norway, though the financial terms were not disclosed.

Implementation
Indicative cost
High (€500k–€5M)
Time to results
Long (> 3 years)
Staffing & skills
~32 staff across legal, scientific and business-development functions

Conditions for success

  • Joint ownership structure merging university and hospital TTOs into a single commercialisation vehicle
  • Dedicated multidisciplinary staff (legal, scientific, business development)
  • Reinvestment of licensing proceeds back into research and inventors

Commonly funded by

National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful